-
1
-
-
79957651158
-
-
National Diabetes Information Clearinghouse Accessed October 3, 2011
-
National Diabetes Information Clearinghouse National diabetes statistics, 2011 http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#y-people Accessed October 3, 2011
-
National Diabetes Statistics, 2011
-
-
-
2
-
-
2342466734
-
Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030
-
DOI 10.2337/diacare.27.5.1047
-
S. Wild, G. Roglic, A. Green Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053 (Pubitemid 38579764)
-
(2004)
Diabetes Care
, vol.27
, Issue.5
, pp. 1047-1053
-
-
Wild, S.1
Roglic, G.2
Green, A.3
Sicree, R.4
King, H.5
-
3
-
-
33749916374
-
-
Food and Drug Administration Accessed October 3, 2011
-
Food and Drug Administration Guideline for Industry Studies in support of special populations: geriatrics http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm073131.pdf August 1994 Accessed October 3, 2011
-
(1994)
Guideline for Industry Studies in Support of Special Populations: Geriatrics
-
-
-
4
-
-
59049091826
-
Pharmacological management of glycemic control in the geriatric patient with type 2 diabetes mellitus
-
J.J. Neumiller, S.M. Setter, B.J. Gates Pharmacological management of glycemic control in the geriatric patient with type 2 diabetes mellitus Consult Pharm 24 2009 45 63
-
(2009)
Consult Pharm
, vol.24
, pp. 45-63
-
-
Neumiller, J.J.1
Setter, S.M.2
Gates, B.J.3
-
5
-
-
0035114670
-
Management of type 2 diabetes mellitus in the elderly: Special considerations
-
J. Rosenstock Management of type 2 diabetes mellitus in the elderly: special considerations Drugs Aging 18 2001 31 44 (Pubitemid 32182131)
-
(2001)
Drugs and Aging
, vol.18
, Issue.1
, pp. 31-44
-
-
Rosenstock, J.1
-
6
-
-
2142769878
-
Treatment of patients over 64 years of age with type 2 diabetes: Experience from nateglinide pooled database retrospective analysis
-
DOI 10.2337/diacare.26.7.2075
-
S. Del Prato, R.J. Heine, L. Keilson Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis Diabetes Care 26 2003 2075 2080 (Pubitemid 41184255)
-
(2003)
Diabetes Care
, vol.26
, Issue.7
, pp. 2075-2080
-
-
Del Prato, S.1
Heine, R.J.2
Keilson, L.3
Guitard, C.4
Shen, S.G.5
Emmons, R.P.6
-
7
-
-
67651245065
-
Potentially severe drug interactions in elderly outpatients: Results of an observational study of an administrative prescription database
-
A. Nobili, L. Pasina, M. Tettamanti Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database J Clin Pharm Ther 34 2009 377 386
-
(2009)
J Clin Pharm Ther
, vol.34
, pp. 377-386
-
-
Nobili, A.1
Pasina, L.2
Tettamanti, M.3
-
8
-
-
67649510151
-
Medication errors in elderly people: Contributing factors and future perspectives
-
D. Fialová, G. Onder Medication errors in elderly people: contributing factors and future perspectives Br J Clin Pharmacol 67 2009 641 645
-
(2009)
Br J Clin Pharmacol
, vol.67
, pp. 641-645
-
-
Fialová, D.1
Onder, G.2
-
9
-
-
0032434422
-
Estimates on the incidence of antidiabetic drug-induced severe hypoglycaemia in Hong Kong
-
DOI 10.1002/(SICI)1099-1557(199811/12)7:6<411::AID-PDS379>3.0.CO;2- U
-
T.Y. Chan Estimates on the incidence of antidiabetic drug-induced severe hypoglycaemia in Hong Kong Pharmacoepidemiol Drug Saf 7 1998 411 414 (Pubitemid 29047898)
-
(1998)
Pharmacoepidemiology and Drug Safety
, vol.7
, Issue.6
, pp. 411-414
-
-
Chan, T.Y.K.1
-
11
-
-
68149117576
-
Hypoglycemia unawareness in older compared to middle-aged patients with type 2 diabetes
-
J.P. Bremer, K. Jauch-Chara, M. Hallschmid Hypoglycemia unawareness in older compared to middle-aged patients with type 2 diabetes Diabetes Care 32 2009 1513 1517
-
(2009)
Diabetes Care
, vol.32
, pp. 1513-1517
-
-
Bremer, J.P.1
Jauch-Chara, K.2
Hallschmid, M.3
-
13
-
-
0022461548
-
Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
-
M.A. Nauck, E. Homberger, E.G. Siegel Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses J Clin Endocrinol Metab 63 1986 492 498 (Pubitemid 16035703)
-
(1986)
Journal of Clinical Endocrinology and Metabolism
, vol.63
, Issue.2
, pp. 492-498
-
-
Nauck, M.A.1
Homberger, E.2
Siegel, E.G.3
-
14
-
-
0031033531
-
Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
-
DOI 10.1007/s001250050664
-
J. Rachman, B.A. Barrow, J.C. Levy Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Diabetologia 40 1997 205 211 (Pubitemid 27060294)
-
(1997)
Diabetologia
, vol.40
, Issue.2
, pp. 205-211
-
-
Rachman, J.1
Barrow, B.A.2
Levy, J.C.3
Turner, R.C.4
-
15
-
-
0024338802
-
GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans
-
DOI 10.1007/BF01540341
-
B.T. Schjoldager, P.E. Mortensen, J. Christiansen GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans Dig Dis Sci 34 1989 703 708 (Pubitemid 19139353)
-
(1989)
Digestive Diseases and Sciences
, vol.34
, Issue.5
, pp. 703-708
-
-
Schjoldager, B.T.G.1
Mortensen, P.E.2
Christiansen, J.3
Orskov, C.4
Holst, J.J.5
-
16
-
-
0027533758
-
Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
-
A. Wettergren, B. Schjoldager, P.E. Mortensen Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man Dig Dis Sci 38 1993 665 673 (Pubitemid 23121274)
-
(1993)
Digestive Diseases and Sciences
, vol.38
, Issue.4
, pp. 665-673
-
-
Wettergren, A.1
Schjoldager, B.2
Mortensen, P.E.3
Myhre, J.4
Christiansen, J.5
Holst, J.J.6
-
17
-
-
60549097258
-
Targeting incretins in type 2 diabetes: Role of GLP-1 receptor agonists and DPP-4 inhibitors
-
R.E. Pratley, M. Gilbert Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors Rev Diabet Stud 5 2008 73 94
-
(2008)
Rev Diabet Stud
, vol.5
, pp. 73-94
-
-
Pratley, R.E.1
Gilbert, M.2
-
18
-
-
0034108646
-
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
-
DOI 10.1021/jm9909645
-
L.B. Knudsen, P.F. Nielsen, P.O. Huusfeldt Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J Med Chem 43 2000 1664 1669 (Pubitemid 30304999)
-
(2000)
Journal of Medicinal Chemistry
, vol.43
, Issue.9
, pp. 1664-1669
-
-
Knudsen, L.B.1
Nielsen, P.F.2
Huusfeldt, P.O.3
Johansen, N.L.4
Madsen, K.5
Pedersen, F.Z.6
Thogersen, H.7
Wilken, M.8
Agerso, H.9
-
19
-
-
2342599057
-
One Week's Treatment with the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and - and Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes
-
DOI 10.2337/diabetes.53.5.1187
-
K.B. Degn, C.B. Juhl, J. Sturis One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes Diabetes 53 2004 1187 1194 (Pubitemid 38569002)
-
(2004)
Diabetes
, vol.53
, Issue.5
, pp. 1187-1194
-
-
Degn, K.B.1
Juhl, C.B.2
Sturis, J.3
Jakobsen, G.4
Brock, B.5
Chandramouli, V.6
Rungby, J.7
Landau, B.R.8
Schmitz, O.9
-
20
-
-
0036189831
-
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
-
DOI 10.1007/s00125-001-0719-z
-
H. Agersø, L.B. Jensen, B. Elbrønd The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 45 2002 195 202 (Pubitemid 34208381)
-
(2002)
Diabetologia
, vol.45
, Issue.2
, pp. 195-202
-
-
Agerso, H.1
Jensen, L.B.2
Elbrond, B.3
Rolan, P.4
Zdravkovic, M.5
-
21
-
-
0036676385
-
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects
-
DOI 10.2337/diacare.25.8.1398
-
B. Elbrønd, G. Jakobsen, S. Larsen Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects Diabetes Care 25 2002 1398 1404 (Pubitemid 41071152)
-
(2002)
Diabetes Care
, vol.25
, Issue.8
, pp. 1398-1404
-
-
Elbrond, B.1
Jakobsen, G.2
Larsen, S.3
Agerso, H.4
Jensen, L.B.5
Rolan, P.6
Sturis, J.7
Hatorp, V.8
Zdravkovic, M.9
-
22
-
-
83555169534
-
No difference in the pharmacokinetic profile of liraglutide when administered as a single dose to young and elderly healthy subjects
-
(Abstract 460-P)
-
B. Damholt, G. Golor, W. Wierich No difference in the pharmacokinetic profile of liraglutide when administered as a single dose to young and elderly healthy subjects Diabetes 54 Suppl 1 2005 A114 (Abstract 460-P)
-
(2005)
Diabetes
, vol.54
, Issue.SUPPL. 1
, pp. 114
-
-
Damholt, B.1
Golor, G.2
Wierich, W.3
-
23
-
-
84855255292
-
-
European Medicines Agency Accessed October 3, 2011
-
European Medicines Agency Victoza (liraglutide) http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/001026/human-med-001137. jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125& jsenabled=true Accessed October 3, 2011
-
Victoza (Liraglutide)
-
-
-
24
-
-
62449129181
-
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)
-
M. Marre, J. Shaw, M. Brndle Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) Diabetic Med 26 2009 268 278
-
(2009)
Diabetic Med
, vol.26
, pp. 268-278
-
-
Marre, M.1
Shaw, J.2
Brndle, M.3
-
25
-
-
62449169287
-
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes
-
M.A. Nauck, A. Frid, K. Hermansen Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes Diabetes Care 32 2009 84 90
-
(2009)
Diabetes Care
, vol.32
, pp. 84-90
-
-
Nauck, M.A.1
Frid, A.2
Hermansen, K.3
-
26
-
-
59449101432
-
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): Randomized, 52-week, phase III, double-blind, parallel-treatment trial
-
A. Garber, R. Henry, R. Ratner Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomized, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 2009 473 481
-
(2009)
Lancet
, vol.373
, pp. 473-481
-
-
Garber, A.1
Henry, R.2
Ratner, R.3
-
27
-
-
67650066860
-
Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD)
-
B. Zinman, J. Gerich, J. Buse Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD) Diabetes Care 32 2009 1224 1230
-
(2009)
Diabetes Care
, vol.32
, pp. 1224-1230
-
-
Zinman, B.1
Gerich, J.2
Buse, J.3
-
28
-
-
69949117621
-
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial
-
D. Russell-Jones, A. Vaag, O. Schmitz Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial Diabetologia 52 2009 2046 2055
-
(2009)
Diabetologia
, vol.52
, pp. 2046-2055
-
-
Russell-Jones, D.1
Vaag, A.2
Schmitz, O.3
-
29
-
-
77953647320
-
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6)
-
3947
-
J. Buse, J. Rosenstock, G. Sesti Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6) Lancet 4 2009 374 3947
-
(2009)
Lancet
, vol.4
, pp. 374
-
-
Buse, J.1
Rosenstock, J.2
Sesti, G.3
-
31
-
-
0032875210
-
Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus
-
DOI 10.1046/j.1365-2796.1999.00528.x
-
L. Landstedt-Hallin, A. Englund, U. Adamson, P.E. Lins Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus J Intern Med 246 1999 299 307 (Pubitemid 29426449)
-
(1999)
Journal of Internal Medicine
, vol.246
, Issue.3
, pp. 299-307
-
-
Landstedt-Hallin, L.1
Englund, A.2
Adamson, U.3
Lins, P.-E.4
-
32
-
-
78049365082
-
Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase
-
M. Malm-Erjeflt, I. Bjørnsdottir, J. Vanggaard Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase Drug Metab Dispos 38 2010 1944 1953
-
(2010)
Drug Metab Dispos
, vol.38
, pp. 1944-1953
-
-
Malm-Erjeflt, M.1
Bjørnsdottir, I.2
Vanggaard, J.3
-
33
-
-
70849121250
-
Metabolism and excretion of [Pal-3H]-liraglutide in human healthy subjects
-
(Abstract 2107-PO)
-
H. Helleberg, M. Malam-Erjefalt, I. Bjornsdottir Metabolism and excretion of [Pal-3H]-liraglutide in human healthy subjects Diabetes 57 Suppl 1 2008 A581 (Abstract 2107-PO)
-
(2008)
Diabetes
, vol.57
, Issue.SUPPL. 1
, pp. 581
-
-
Helleberg, H.1
Malam-Erjefalt, M.2
Bjornsdottir, I.3
-
34
-
-
70849096647
-
Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
-
L.V. Jacobsen, C. Hindsberger, R. Robson, M. Zdravkovic Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide Br J Clin Pharmacol 68 2009 898 905
-
(2009)
Br J Clin Pharmacol
, vol.68
, pp. 898-905
-
-
Jacobsen, L.V.1
Hindsberger, C.2
Robson, R.3
Zdravkovic, M.4
-
35
-
-
80053582283
-
Mild renal impairment has no effect on the efficacy and safety of liraglutide
-
J. Davidson, J. Brett, A. Falahati, D. Scott Mild renal impairment has no effect on the efficacy and safety of liraglutide Endocr Pract 6 2010 1 31
-
(2010)
Endocr Pract
, vol.6
, pp. 1-31
-
-
Davidson, J.1
Brett, J.2
Falahati, A.3
Scott, D.4
-
37
-
-
77949393973
-
Management of hypertension in the elderly patient
-
G.S. Stokes Management of hypertension in the elderly patient Clin Interv Aging 4 2009 379 389
-
(2009)
Clin Interv Aging
, vol.4
, pp. 379-389
-
-
Stokes, G.S.1
-
38
-
-
37149006184
-
Management of type 2 diabetes in treatment-naive elderly patients: Benefits and risks of vildagliptin monotherapy
-
DOI 10.2337/dc07-1188
-
R.E. Pratley, J. Rosenstock, F.X. Pi-Sunyer Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy Diabetes Care 30 2007 3017 3022 (Pubitemid 350255235)
-
(2007)
Diabetes Care
, vol.30
, Issue.12
, pp. 3017-3022
-
-
Pratley, R.E.1
Rosenstock, J.2
Pi-Sunyer, F.X.3
Banerji, M.A.4
Schweizer, A.5
Couturier, A.6
Dejager, S.7
-
39
-
-
70350452161
-
Alogliptin use in elderly people: A pooled analysis from phase 2 and 3 studies
-
R.E. Pratley, T. McCall, P.R. Fleck Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies J Am Geriatr Soc 57 2009 2011 2019
-
(2009)
J Am Geriatr Soc
, vol.57
, pp. 2011-2019
-
-
Pratley, R.E.1
McCall, T.2
Fleck, P.R.3
|